Genmab A/S
GMABDrugs in Pipeline
25
Phase 3 Programs
13
Upcoming Catalysts
4
Next Catalyst
Jun 14, 2026
11wMarket Overview
Stock performance and key metrics
4 upcoming, 2 past
Cyclophosphamide
Diffuse Large B-Cell Lymphoma
Pembrolizumab
Non Small Cell Lung Cancer Metastatic
Prednisone
Follicular Lymphoma (FL)
Paclitaxel
Platinum-resistant Ovarian Cancer
Zalutumumab
Head and Neck Cancer
Epcoritamab
Diffuse Large B-Cell Lymphoma
Rina-S
Endometrial Cancer
Oxaliplatin
Diffuse Large B-Cell Lymphoma
Docetaxel
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Investigator's Choice Chemotherapy
Diffuse Large B-Cell Lymphoma
Acasunlimab
Cutaneous Melanoma
Lenalidomide
Diffuse Large B-Cell Lymphoma
Doxorubicin
B-Cell Non-Hodgkin Lymphoma
HuMax-CD4
Cutaneous T-Cell Lymphoma
Venetoclax
Relapsed/Refractory Chronic Lymphocytic Leukemia
Acasunlimab in combination with docetaxel (in a single expansion cohort)
Solid Tumors
gemcitabine and oxaliplatin
Diffuse Large B-Cell Lymphoma
GEN1286
Advanced Solid Tumor
GEN1042
Malignant Solid Tumor
Carboplatin
High Grade Epithelial Ovarian Cancer
tisotumab vedotin
Solid Tumor
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
Breast Cancer, Breast Neoplasms
Ibrutinib
Non-Hodgkin Lymphoma
Enapotamab vedotin (HuMax-AXL-ADC)
Ovarian Cancer
Epcoritamab (monotherapy)
Diffuse Large B Cell Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cyclophosphamide | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Pembrolizumab | Phase 3 | Non Small Cell Lung Cancer Metastatic | - | - |
Prednisone | Phase 3 | Follicular Lymphoma (FL) | - | - |
Paclitaxel | Phase 3 | Platinum-resistant Ovarian Cancer | - | - |
Zalutumumab | Phase 3 | Head and Neck Cancer | - | - |
Epcoritamab | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Rina-S | Phase 3 | Endometrial Cancer | - | - |
Oxaliplatin | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Docetaxel | Phase 3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | - | - |
Investigator's Choice Chemotherapy | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Acasunlimab | Phase 3 | Cutaneous Melanoma | - | - |
Lenalidomide | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Doxorubicin | Phase 3 | B-Cell Non-Hodgkin Lymphoma | - | - |
HuMax-CD4 | Phase 2 | Cutaneous T-Cell Lymphoma | - | - |
Venetoclax | Phase 2 | Relapsed/Refractory Chronic Lymphocytic Leukemia | - | - |
Acasunlimab in combination with docetaxel (in a single expansion cohort) | Phase 2 | Solid Tumors | - | - |
gemcitabine and oxaliplatin | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
GEN1286 | Phase 2 | Advanced Solid Tumor | - | - |
GEN1042 | Phase 2 | Malignant Solid Tumor | - | - |
Carboplatin | Phase 2 | High Grade Epithelial Ovarian Cancer | - | - |
tisotumab vedotin | Phase 2 | Solid Tumor | - | - |
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells. | Phase 2 | Breast Cancer, Breast Neoplasms | - | - |
Ibrutinib | Phase 2 | Non-Hodgkin Lymphoma | - | - |
Enapotamab vedotin (HuMax-AXL-ADC) | Phase 2 | Ovarian Cancer | - | - |
Epcoritamab (monotherapy) | Phase 2 | Diffuse Large B Cell Lymphoma | - | - |